N/A
N=11
A Prospective Evaluation of Infraorbital Filler Injection
Dermal Filler · Rejuvenation
Bottom Line
View on ClinicalTrials.gov: NCT05694286 ↗Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcome: Primary: Volumetric Change in Infraorbital Treatment Baseline to Each Post-intervention Timepoint Day 14, Day 30, and Day 90 — -0.026; -0.065; -0.108 cc
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Juvederm Volbella XC hyaluronic acid dermal filler injection (Procedure)
- Age
- Adult, Older Adult · 22+ yrs
- Sex
- Female
- Sponsor
- University of Pennsylvania
- Primary completion
- Apr 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Volumetric Change in Infraorbital Treatment Baseline to Each Post-intervention Timepoint Day 14, Day 30, and Day 90 |
-0.026; -0.065; -0.108 | — |
| SECONDARY Patient Satisfaction With Validated the Questionnaire FACE-Q |
46.4; 59.9; 61.4; 66.6; 63.4; 55.4 | — |
Summary
The goal of this clinical trial is to measure the facial volumetric changes over time in patients injected with hyaluronic acid dermal filler (Juvéderm Volbella XC) in the infraorbital (under eye) region. Participants will be injected with Juvéderm Volbella XC filler and asked to return for 3D photography at 2 weeks, 1 month, and 3 months post-injection.
Eligibility Criteria
Inclusion Criteria
- female
- age 22 to 65
- interested in filler injections to reduce undereye volume loss
Exclusion Criteria
- male
- age 65
- prior undereye filler
- filler/neurotoxin injection within the past 12 months
- prior facial cosmetic surgery
- prior facial trauma
- planned dental work within next 2 weeks
- travel 1 week prior or 2 weeks after injection
Data sourced from ClinicalTrials.gov (NCT05694286). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.